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In the hope of a better, brighter future;  
This is for my sister Nea. The world is yours.  
  
  
ABSTRACT 
The aim of this thesis was to follow the prevalence of human papillomavirus in the oral cavi-
ty and in the cervix in youth during the period of 2008-2015, a period when HPV vaccination 
was gradually introduced to young girls in Sweden. In addition, we explored the prevalence 
of HPV in hypopharyngeal cancer during the period 2000-2012 on the basis that there has 
been an epidemic of HPV positive tonsillar and base of tongue cancer, which arise in loca-
tions with close physiological proximity to the hypopharynx. 
The main questions addressed were whether HPV prevalence is similar within different co-
horts of Swedish youth, how the prevalence changes over time and after the introduction of 
the HPV vaccines, and if the increased proportion of HPV positive oropharyngeal cancer is 
mirrored also in hypopharyngeal cancer. Since the prevalence of oral and genital HPV previ-
ously observed at a Stockholm youth clinic was high during the period of 2008-2011, there 
was an opportunity to compare these data to the HPV prevalence in different geographical 
locations and at other time points. The strong Swedish tradition of biobanking granted access 
to a relatively large sample of hypopharyngeal cancers, and the high prevalence of HPV in 
oropharyngeal cancers in Sweden made it credible that HPV would also be present at detect-
able levels in hypopharyngeal cancer and make it possible to detect changes occurring in the 
HPV prevalence in this cancer type.  
To investigate these matters, oral and cervical samples were analyzed for the presence of 
HPV DNA, a questionnaire was used to investigate the sexual experiences of youth, and HPV 
DNA and p16 expression was analyzed in relation to survival in samples of hypopharyngeal 
cancer.  
In Paper I, we could show that oral HPV prevalence was significantly less common in high 
school students from a middle sized municipality in Sweden (1.8%) than what was observed 
in 2009-2011 in the Stockholm youth clinic(9.3%). 
In Paper II, we could show that there were no differences between HPV vaccinated and non-
vaccinated women regarding condom use and self-reported STI history, however, vaccinated 
women were more likely to have had vaginal intercourse and one-night stands (p=0.005, and 
p=0.046, respectively).  
In Paper III, we found a low oral HPV prevalence also at the Stockholm youth clinic (1.4%) 
in 2013-2014 which was lower than what was previously observed at the same clinic (p= 
0.00001). Cervical HPV 16, 31 and 70 prevalence was now less common in vaccinated than 
in non-vaccinated individuals (p =0.0002,  p=0.019, and p=0.006, respectively).  
In Paper IV, we expanded the cohort from paper 3 to also include samples from the fall of 
2014 and the spring of 2015. Oral HPV prevalence remained low (1.5%) and cervical HPV 
16, 31 and 6 were less common in vaccinated than in non-vaccinated women (p=0.0006, 
p=0.038 and p=0.009, respectively).  
In Paper V, we could show that the proportion of HPV positive cases of hypopharyngeal can-
cer have not increased in Stockholm and that p16 is a poor surrogate marker of active HPV 
infection in this cancer type.  
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1 INTRODUCTION 
1.1 WHAT IS CANCER? 
Today, cancer is one of the most common causes of death worldwide and was estimated to 
have caused approximately 8.2 million human deaths in 2012 and, over a lifetime; more than 
one in three will be diagnosed with cancer
1,2
. As a consequence, the search for a cure for can-
cer has been a priority for the scientific community for decades, and in 1971, US President 
Richard Nixon signed the National Cancer Act; officially declaring a war on cancer
3
. Yet, in 
2016 we remain far from finding the final solution to the cancer issue.  
Why is it then that we have not come further? One critical point to be made is that cancer is 
not one disease; rather, it’s a number of diseases that share the characteristics of uncontrolled 
cellular division and the ability of the cells to expand beyond the boundaries of their original 
compartment. Most cell types in the body can indeed give rise to cancer, resulting in a vast 
diversity in clinical presentation, as well as in prognosis for the person affected. As such, the 
causes and potential treatment options for cancer diseases are widely disperse and thus, a large 
amount of branches have emerged within the field of cancer research. One such field is the 
field of tumor virology. 
1.2 THE EMERGENCE TUMOR VIROLOGY 
While the germ theory of disease was first proposed in the mid-16
th
 century, the idea that infec-
tions might also be a potential cause of cancer was foreign to most researchers. Following the 
famous experiments by Francis Peyton Rous, showing that filtered extracts from chicken tumors 
were indeed transferrable, this perception slowly began to change
4
. The subsequent discovery of 
what became known as the Rous sarcoma virus (RSV) was to be the first of many tumor causing 
viruses discovered in the following century. 
The identification of the first virus linked to human cancer was made in the 1960’s and can be 
seen as a direct result of the fortunate meeting between the pathologist Michael Anthony Epstein 
and the surgeon  Denis Parsons Burkitt
5
. The latter had recently described an endemic form of 
lymphoma in children (Burkitt’s lymphoma) predominantly found in equatorial Africa and it 
was soon established that the tumors contained large quantities of viral particles. The virus was 
named Epstein-Barr virus (EBV) after the researchers who discovered it; Michael Anthony Ep-
stein and Yvonne Barr
6
. The transforming capabilities of the virus were later confirmed experi-
mentally by, among others, Gertrude Henle and Harald zur Hausen. Since then several viruses 
such as human papillomavirus (HPV) hepatitis B, hepatitis C, human T-cell leukemia virus 1 
and Merkel Cell polyomavirus have been demonstrated to be involved in human cancer, and the 
focus of this thesis is on the first of these; the HPV family
7–10
.   
1.3 HISTORY OF THE HUMAN PAPILLOMAVIRUS  
The essential work on Epstein-Barr virus was far from the last contribution Harald zur Hausen 
would make to the field of tumor virology. His major field of interest, however, afterwards 
changed to another virus family, HPV.  
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Already back in 1949, Maurice J Strauss and colleagues had discovered the presence of virus-
like particles (VLPs) in skin papillomas
11
. At that time, the importance of these particles was to 
remain a mystery yet for some decades.  
By the mid 1980’s, zur Hausen and colleagues had discovered that Human Papillomavirus 
(HPV) types 16 and 18 are prevalent in cervical cancer
12–14
. Although this was not the first find-
ing of an oncogenic virus in humans, the discovery was still ground breaking in its own right. As 
it turns out, HPV 16 and 18 together cause  approximately 75% of all cervical cancer (CC), the 
fourth  most common type of cancer in women
1,15
. 
1.4 HPV STRUCTURE AND PROTEINS  
While previously classified as a part of the family Papovaviridae together with the polyoma-
viruses and SV40, the papillomaviruses are today recognized as constituting their own viral fam-
ily; Papillomaviridae
16
. Within the Papillomaviridae family there are a number of genera, indi-
cated by Greek letters, which are then further subdivided into species and, finally, types. To 
date, there are 202 confirmed HPV types and new ones are being described at an increasing rate 
since the development of metagenomic sequencing
17,18
. While all HPVs are epitheliotropic, 
some preferentially infect cutaneous epithelia, and others are mainly found in mucosal epithelia. 
Depending on their oncogenic capabilities, the HPV types are classified as either low-risk (LR) 
or high-risk (HR), with some types being assigned as putative, or potential, HR due to a lack of 
conclusive evidence of their oncogenicity.  
All HPVs have a ~8kb double stranded DNA genome with a low degree of genomic diversity 
within species and a low mutation rate. The current classification system of HPV is based on 
sequence relatedness of the L1 gene
16
.  
The HPV genome is frequently described as consisting of three major regions; the non-coding 
long control region (LCR), the early region, and the late region, encoding the early and late pro-
teins respectively
19,20
.  
All of the early proteins possess more than one func-
tion during infection and HPV induced transfor-
mation, and to describe all functions exerted by these 
proteins would make a book in its own right. Below, 
some of the main functions of the HPV early proteins 
have been summarized.  
1.4.1 Early proteins 
The early region of HPVs has eight open reading 
frames (ORFs) that, often, produce the proteins E1, 
E2 and E4-E7. While the E3 gene, is not known to 
code for a protein, the E8 gene forms a fusion protein with E2 that seems to be repressing viral 
transcription
21
. Here follows a summary of the functions of the major HPV early gene tran-
scripts.   
Figure 1. Human Papillomavirus Particle 
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1.4.1.1 E1 and E2 
The HPV E1 and E2 proteins are expressed early in the viral lifecycle and are necessary for the 
virus to integrate into the host genome. After viral integration, one or both of the genes may be 
lost. E2 loss in particular has been associated with high-grade cervical lesions, making it a com-
monly used marker of viral integration
22,23
. It has also been shown that loss of E2 is related to a 
worse clinical outcome in several types of cancer. This has been shown to be the case for both 
cervical cancer, and more recently, tonsillar and base of tongue cancer, although evidence for the 
latter remain inconclusive 
23–26
.  
1.4.1.2 E4 
E4 is a protein that is highly prevalent during latter stages of HPV infection and coincides with 
vegetative viral genome amplification and similarities in E4 intracellular localization suggest an 
evolutional functional retention 
27,28
. The protein is expressed as an E1^E4 fusion protein that is 
involved in the sequestration of viral 
protein, the transcript may also be 
involved in the regulation of E2 ex-
pression
29,30
 .   
1.4.1.3 E5, E6 and E7 
The proteins E5, E6 and E7 are the 
HPV products with the most well doc-
umented oncogenic activity in HR 
HPV types. These proteins often ex-
hibit different function or binding ca-
pabilities in LR HPVs, as compared to 
HR HPVs.    
1.4.1.4 E5 
E5 is the smallest of the oncoproteins 
and several different subtypes exist 
among HPVs of different oncogenic capacity. In fact, not all genera of HPV express E5 at all. 
The evolutionary retention of E5 in many HR HPVs suggests that, while not necessary for cellu-
lar transformation, E5 gives an added benefit to the virus. Several types of E5 proteins have also 
been shown to have independent transforming activity in murine keratinocytes and fibroblasts. 
1.4.1.5 E6 
The E6 protein of HR HPV types has a well-documented ability to immortalize cells of various 
origins in vitro and, in some instances, even induce transformation independent of other viral 
proteins
31,32
. In HR HPVs E6 is best known for its ability to interfere with p53, “the guardian of 
the genome”33. E6 binds to the E6-associated protein (E6AP), the E6/E6AP complex targets 
p53, causing it to become ubiquitinated and degraded in the proteasome. While p53 degradation 
Figure 2. Organization of the HPV16 genome 
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takes place in most HPV 16 associated cancers, there are documented cases of HPV-positive 
cervical cancer where p53 expression remains seemingly unaffected. It is likely that in these 
tumors, an alternative mechanism of p53 independent postmitotic checkpoint alteration may be 
in play. While the exact details of this proposed mechanism remain unknown, Cdk1 is implicat-
ed to play a crucial role as a mediator
34
.   
Another important function of  HR HPV E6 is its ability to interact with so called PDZ 
domains
35
. Such domains are found in a number of other cellular proteins, several of which are 
also targets of E6 binding including; hDly, hScrib, MUPP1, 14-3-3ζ, Na/ H exchange regulatory 
factor 1, PATJ, PDZRN3/LNX3 as well as MAGI and TIP family proteins
35–46
. Interestingly, 
while HR HPV E6s have a class 1 PDZ binding motif at the C-terminus, no such motif is present 
in LR HPVs and this could be a contributing factor to why different HPVs have varying onco-
genic capacity
35,47,48
. Furthermore, while the E6 PDZ binding domain has been found to be facil-
itating efficient growth in human foreskin keratinocytes, it does not appear essential for HPV 
induced immortalization
40
.  
Another interesting feature of E6 activity is its interaction with the WNT pathway. In association 
with E6AP, E6 stabilizes β-catenin and works to augment WNT signaling49. Additionally, E6 
has been shown to cause translocation of β-catenin, possibly in an EGFR related manner50.  
1.4.1.6 E7 
E7 is an oncoprotein that, in some contexts, has an even more potent transforming activity than 
E6
51
. In HR HPVs E7 de-regulates cell cycle control, primarily by competitively binding to pRb, 
and thus releasing bound E2F1. E2F1 will then transactivate cell cycle related genes such as 
cyclin A and E, subsequently stimulating cell cycle transition by dysregulating the G1/S check-
point. Also the E7 protein of LR HPV has the ability to bind pRb but does so to a lesser extent
52
.  
In addition to their transforming activities, both E5 and E7 have been described to interfere with 
the cellular antigen processing machinery (APM) and downregulate the expression of the major 
histocompatibility complex (MHC)
53,54
 . This association has not been verified in oropharyngeal 
squamous cell carcinomas.  
E7 has also been used as a target in the development of both prophylactic and therapeutic vac-
cines. The usage of E7 in therapeutic vaccines is particularly exciting as there are currently no 
therapeutic vaccines for HPV related disease on the market. A 2014 study showed that oral vac-
cination with Lactobacillus Casei expressing modified E7 was able to downgrade CIN3 lesions 
to CIN2 in 9 weeks
55
.  
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Figure 3. Oncogenic mechanisms of the HPV E6 and E7proteins 
 
1.4.2 Late proteins 
The transcripts of the two late proteins L1 and L2 were identified following the discovery of the 
early gene transcripts. As postulated, the L1 and L2 proteins are structural proteins that together 
make up the viral capsid
56
. 
1.4.2.1 L1 
L1 is the major capsid protein of HPV. In total, the capsid consist of 72 L1 pentamers, each of 
which consist of an outwards facing star like structure and a trunk through which runs a channel 
to the capsid interior. The protein has the ability to self-assemble into virus-like particles (VLP) 
both with and without L2 in a fashion similar to what had previously been observed for the VP1 
protein of the closely related polyomaviruses
57–60
.  
The HPV vaccines currently on the market consist of empty L1 capsids of different HPV types.                                                                                                                            
Already in 1987 it was shown that antisera produced using purified HPV particles was reactive 
against L1
56
. At a relatively early stage it was also shown that the human antibody-reactive 
epitope of L1 proteins were specific for different HPVs with a certain degree of cross-reactivity, 
a fact that has become critical in the development of HPV vaccines
61,62
.  
1.4.2.2 L2 
For each pentamer present in the viral capsid, there is up to one molecule of the minor capsid 
protein L2, although the average virion seems to contain somewhat fewer molecules randomly 
distributed between the binding sites
63,64
.  
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It would seem that the L2 protein is involved in encapsidating DNA in the virions, since only 
L2, and not L1 has the capability to bind HPV DNA
65
. Furthermore, it has been found that cap-
sids with mutated L2 have a 10-fold decrease in the ability to encapsidate viral DNA. Interest-
ingly, this reduced ability to take up viral DNA did not seem to fully explain the observed de-
crease in infectiousness of the mutant particles, highlighting  the fact that the  protein has multi-
ple roles in the viral life cycle
66
. Examples of such functions are facilitating capsid uptake into 
the target cells and mediation of viral entry into the ER
67,68
.  
L2 is more evolutionarily conserved than L1, and it has therefore been suggested as a potential 
tool in vaccine development; however, antibody titers produced against L2 have been weak in 
comparison to responses elicited by L1 vaccines
69
. No L2 based vaccines are currently in clini-
cal use.     
1.5 HPV LIFE CYCLE 
As previously mentioned, HPV infect epithelial cells. More specifically, HPV infects epithelial 
cells of the basal lamina of stratified epithelium through micro-wounds by interacting with cell 
surface heparin proteoglycans
70,71
. Over time, these infected cells divide and the daughter cells 
spread towards the epithelial surface. In an HPV driven lesion, different cellular layers are in 
different phases of the cell cycle and produce different viral proteins. Somewhat simplified, the 
lower layers produce the oncoproteins E6 and E7, thus pushing the cells to divide. Further up in 
the lesion, E4 is produced and the genome is amplified. In the cells closest to the surface, the 
capsid proteins L1 and L2 are produced and the viral genomes are packed in capsids (figure 3).  
1.6 PERSISTANCE AND CLEARANCE OF HPV INFECTIONS 
It is likely that there is a genetic component to HPV infections persisting in an individual. For 
example, it appears as if cervical HPV infection is more common in young women of African 
American ethnicity than in women of European American ethnicity although incidence rates 
were the same
72
. Furthermore, it seems that pregnancy is protective against persistent cervical 
HPV infection
73
.  Genetic variations in the virus can also be associated with a less efficient viral 
clearance; for example, it has been shown that variations within HPV 16 E6 and E2 increase the 
risk of persistent infection
74
.  
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1.7 HPV IN DISEASE 
As earlier mentioned, HPV types can be divided into HR and LR types depending on their onco-
genic potential. According to the 2007 IARC monograph on papillomaviruses, approximately 15 
HPV mucosal types should be considered as high-risk. These types are HPV 16, 18, 39, 45, 59, 
68, 26, 31, 33, 35, 51, 52, 55, 56, and 58
75
. Low-risk mucosal types are HPV 6, 11, 40, 42, 51, 
53, 54, 57, 66, 73, 82, 83, and 84
75
. There are varying degrees of evidence on the oncogenicity 
of the different HPV types in different cancer sites; however, in the majority of HPV related 
malignancies, HPV 16 is the dominating type
75
.  
In 2009, before introduction of public HPV vaccination in Sweden, the estimated cost of HPV 
related cervical cancer and genital warts alone was approximately €106.6 million76.  
1.7.1 HPV-associated cancers 
1.7.1.1 HPV in anogenital cancers 
Around 1970, there was a suspicion that papillomaviruses, which had been found in different 
types of human warts, could in fact also be causing cancer, however, evidence at this time was 
scarce and Herpes simplex virus (HSV) remained the major suspect in the hunt for a virus caus-
ing anogenital cancers
77–79
. In 1971, there was a case report showing what appeared to be papil-
lomavirus particles in an anal carcinoma in situ, however, the first cancer where enough evi-
dence could be gathered to support a causal role for HPV was cancer of the cervix uteri 
13,80
 . 
Since then HPV, has also been found in a considerable portion of vulvar cancer, vaginal cancer, 
penile cancer and anal 
81–85
. 
 
Below, cancer of the cervix uteri will be described followed by a 
more superficial discussion on HPV in other anogenital sites. 
Figure 4. HPV lifecycle 
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1.7.1.2 Cervical cancer 
With 528 000 newly diagnosed cases worldwide in 2012, carcinoma of the uterine cervix is the 
fourth most common cancer in women and a major cause of cancer related death, accounting for 
7.5% of cancer related deaths in women. The geographical discrepancy in the prevalence and 
mortality of cervical cancer is pronounced; more than 85% of cervical cancer deaths occur in 
less developed areas of the world with the highest mortality being reported for Eastern and Mid-
dle Africa, and Melanesia
86
.   
There are two main types of cervical cancer; squamous cell carcinoma and adenocarcinoma. 
These two share many of the same risk factors and both have been associated with HPV in pro-
spective epidemiological studies
87
. Of the two types, squamous cell carcinoma accounts for the 
majority of all cases and approximately 80% of these cancers are caused by either HPV 16 or 18, 
close to all of the rest being caused by other HR HPVs
15
.  
Since long it has been known that invasive cervical cancer is foregone by precancerous lesions, 
which can be defined in different ways.  
One common way of classifying these lesions is by subdividing them into grades of cancer in-
traepithelial neoplasia (CIN), where CIN 1 represents mild abnormal cell growth encompassing 
a maximum of 1/3 of the basal epithelium, CIN 2 represents abnormal cell growth encompassing 
2/3 of the basal epithelium, and CIN 3 spans more than 2/3 of the epithelium and can effectively 
be classified as carcinoma in situ.  
The histological grading of CIN is corresponded by cytological grading in the Bethesda system 
where atypical squamous cells of undetermined significance (ASC-US) is a common result of a 
Papanicolao (Pap) test, which is most often not indicative of cervical carcinoma, but should be 
investigated further, preferably by HPV testing.  
The denomination Low-grade Squamous Intraepithelial Lesion (LSIL) roughly corresponds to 
the presence of a CIN 1, while High-grade Squamous Intraepithelial Lesion corresponds roughly 
to a CIN 2 or 3. The system also includes codes for glandular abnormalities.  
Notably, CIN lesions can be removed through ablative or excisional methods and have a low 
recurrence rate, especially in women with negative posttreatment Pap tests
88,89
.  A fraction of 
CIN lesions will ultimately progress into invasive carcinoma if left untreated, this risk has been 
shown to be low in women who have HPV L1 specific antibodies
90
.  
Tests for screening for atypical cells in the uterine cervix were first invented in the 1920s, inde-
pendently by Georgios Papanicolaou and Aurel Babeş91. Of the two tests, the one that won in-
ternational recognition and was put into routine clinical practice in large parts of the world was 
the Papanicolao (Pap) test. The test, referred to as a conventional pap test, is performed either 
using a spatula, smearing the cells directly onto a glass slide or, more recently by liquid based 
cytology, using a brush, which is suspended in a preservative liquid until analysis.  
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Since the introduction of the Pap test, the proportion of cervical cancers diagnosed at an ad-
vanced stage has decreased in Sweden. Despite its obvious merits; the performance of the Pap 
test is less than optimal. A Pap test is able to distinguish between high grade lesions and other 
conditions with a high specificity of 0.96, but with a rather low sensitivity of only 0.63. Con-
versely, the test can detect any abnormality regardless of grade, with a low specificity of 0.53 
but with a high sensitivity of 0.91
92
.  
The suboptimal performance of the Pap test, together with the emerging possibilities to more 
easily assay for presence of HPV have led to the development of new screening protocols, which 
may now also include screening for HPV.  
When using liquid based cytology, but not conventional cytology, it is possible to use the same 
sample for HPV testing
93
. In Sweden, The National Board of Health and Welfare (Socialstyrel-
sen) now recommends that all women of 30–49 years of age should be offered HPV testing eve-
ry third year, for women of 50–64 years of age testing should be performed every seventh year. 
In case of a positive sample, the HPV test should be followed up by cytology. In women young-
er than 30, Pap testing is still recommended as a primary screening method, partly due to the fact 
that a large proportion of young women are carriers of HR HPV
94
.  Another test that is used in 
some settings is visual inspection with acetic acid (VIA) that is cheap and easy to perform, since 
it in essence only requires some basic tools, a table and acetic acid. The performance of this test 
is similar to that of the Pap test; the test is therefore often the screening method of choice in low 
resource settings
95
. 
An alternative to classical gynecological visits is HPV testing by self-sampling. This method 
gives reliable results as compared to testing at a gynecologist and also allows for women to be 
screened without having to undergo a pelvic exam which is often described as embarrassing 
96,97
. 
Importantly, self-sampling may have potential to reach women who for cultural or other reasons 
choose not to attend gynecological visits.  It may also be an option in low resource settings 
where access to health care facilities is limited and cervical cancer incidence is high. The main 
concern expressed by women who have tried cervical self-sampling is the fear that the procedure 
will not be carried out correctly and that the personal contact with the gynecologist will be lost. 
There also seems to be a generational difference in the acceptance of an at-home test with 
younger women favoring the classical gynecological visits to a higher extent than older wom-
en
97
. It would also seem that educational level is important for women’s likelihood in accepting 
the self-sampling procedure
98
.  
In cervical cancer, overexpression of p16 has often been used as a prognostic marker and a 
marker of active HPV infection. In this setting, p16 as a marker seems to function rather well, 
having a clear correlation to patient 
99,100
. The marker also seems to facilitate diagnosis of 
CIN2+ lesions as compared to using hematoxylin and eosin staining alone for morphological 
evaluation
101
.  
Cervical conization is a common treatment option for CIN lesions and is often carried out using 
either cold knife conization (CKC) or what is known as loop electrosurgical excision procedure 
 10 
(LEEP), however, a subset of the patients are left with residual or recurrent disease. The risk of 
persistent or recurrent disease is increased in patients who remain HPV positive 6 months after 
treatment, and who have conization specimens positive for TPX2 and PD-L1
102
. For cervical 
cancer, treatment can be either fertility sparing or radical. The type of treatment received is criti-
cal for the recovery of the patients, where those undergoing fertility sparing treatment have few-
er lost workdays as compared to patients undergoing more extensive treatment
103
. 
1.7.1.3 Vulvar, penile, anal cancer 
Vulvar, vaginal, penile and anal cancer are not as common as cervical cancer in unscreened 
populations. There are no regular screening methods at present to detect these tumors, however 
antibodies against HPV 16 E6 can be found in 29% of individuals who will later develop anal 
cancer already 10 years before diagnosis
104
. Notably, to present HPV 16 E6 antibodies at this 
time point is rare in other anogenital cancers but common in OPSCC.   
Tumors from other subsites in the vicinity are rarely HPV positive. In fact, despite its anatomical 
proximity to the uterine cervix, endometrial cancer seems to stem mainly from other causes ra-
ther than HPV infection, neither does it seem to play a role in urothelial bladder cancer
105,106
. 
1.7.1.4 HPV in head-neck cancers 
Since long, papillomaviruses have been known to be associated with laryngeal papilloma, and 
while the virus was suspected to have a role also in laryngeal carcinoma, no definitive correla-
tion could be established
107
.   
1.7.1.5 Oropharyngeal cancer, with emphasis on tonsillar and base of tongue cancer  
It was later shown that HPV16 could indeed be found in a number of head neck cancers, with 
the highest prevalence being in oropharyngeal cancers (OPSCC)
108,109
. These and other reports 
lead to the International Agency for Cancer Research (IARC) recognizing HPV as a causative 
agent for oropharyngeal cancer in 2007 alongside the traditional risk factors smoking, and alco-
hol 
75
. Subsequent studies have shown that HPV is primarily found in tonsillar and base of 
tongue cancers (TSCC and BOTSCC), which together constitute a majority of OPSCC. A meta-
analysis by Abogunrin et al. showed that between 2002 and 2012, the prevalence of HPV in 
head-cancers in Europe was 40%, with the highest prevalence being for tonsillar cancer at 
66.4%
110
. A recent study by our research group on tumors from the County of Stockholm has 
demonstrated an even higher incidence, at 80% and 64% for tonsillar and base of tongue cancer 
respectively
111
. This difference may in part be attributable to differences in smoking habits be-
tween countries
112
.  
Determining whether a tumor of the head and neck is caused by HPV has been a matter of de-
bate. To determine if a cancer is HPV driven, using only the presence of HPV DNA in the tumor 
is not conclusive. To detect an active infection, there are a few major approaches. What has 
sometimes been considered the most reliable measure is the detection of HPV E6 and E7 
mRNA
113
. This is optimally done in fresh frozen material, which is not always available at all 
times and especially not for retrospective studies.  
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P16 overexpression has sometimes been used as a pseudomarker of HPV infection and, while 
using p16 alone has now been shown to have a non-satisfactory correlation to the presence of 
HPV DNA in the tumor, using the two markers in combination has shown greater promise
114
.
 
Using HPV DNA and p16 in combination has been shown to be almost as sensitive and specific 
as detection of HPV E6 and E7 mRNA in OPSCC. Approximately 15% of HPV negative head-
neck cancers are p16 positive
115
.  
HPV positive OPSCC is prone to metastasize. Common sites of metastasis include locoregional 
metastases in the head-neck region, as well as distant metastasis in bone and lung. As the metas-
tases generally retain their HPV positivity, HPV positive metastases of cancer of unknown pri-
mary of the head and neck region can be strongly suspected to be of oropharyngeal origin and 
warrant tonsillectomy and/or resection of the tongue base
116–118
.  
As mentioned above, HPV DNA positivity and p16 immunostaining show a relatively good but 
not absolute correlation, however, this correlation is not as good at other cancer sites. A previous 
report from the Tina Dalianis research group showed that for hypopharyngeal cancer, p16 and 
HPV DNA did not seem to correlate to any larger extent
119
. Further data has since been present-
ed by e.g. Sgaramella et al., strengthening the notion that p16 may not be a suitable pseudo-
marker of active infection in head neck cancers outside of the oropharynx
120
.  
The causative role of HPV in OPSCC and the mere fact that the disease is caused by an 
infectious agent is of course interesting from an epidemiological perspective, especially as the 
Figure 5. Anatomy of the pharynx 
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incidence of HPV positive OPSCC is increasing in many parts of the world. As a matter of fact, 
in Sweden, the incidence of HPV TSCC and BOTCC has increased
121
. Moreover, HPV driven 
TSCC and BOTSCC have shown to have a different mutational profile as well as a markedly 
better prognosis than the corresponding HPV negative cancers when given a standard treatment 
regime. For example, in a 2007 study from our research group, patients with HPV positive 
tonsillar cancer had a disease specific survival of 81% while the corresponding figure was 36% 
for patients with HPV negative tonsillar cancer
122
.  This suggests that HPV positive and negative 
TSCC and BOTSCC should be considered as different disease entities in research and clinical 
care.   
1.7.1.6 HPV in hypopharyngeal cancer 
For hypopharyngeal cancer, estimates of the HPV attributable fraction have varied widely, from 
0-82% in different studies
119,123–126
. To what degree this difference is due to methodological dif-
ferences, and to what degree it reflects a true biological difference is unknown.   
Risk factors for hypopharyngeal cancer are the classical risk factors for head neck cancer; smok-
ing and alcohol. The disease is often diagnosed at late stages, since early symptoms are rare, 
which contributes to the poor prognosis associated with these cancers, where only between 15 
and 30% survive beyond five years. Due to the anatomical proximity of the hypopharynx to the 
oropharynx, it is reasonable to assume that a proportion of hypopharyngeal cancers are HPV 
related. Furthermore, the increase in the proportion of HPV positive cases observed in OPSCC 
brings up the question if a similar development is taking place in hypopharyngeal cancer. The 
role of HPV in hypopharyngeal cancer and its relation to p16 expression is explored in paper 5 
in this thesis.  
1.8 HPV IN OTHER CONDITIONS  
Anogenital warts, or condylomata acuminate, are fairly common in the general population with 
an estimated incidence of about 200/100,000, peaking in young adulthood
127
. The condition is 
caused by HPVs and numerous HPV types including both HR and LR types have been found in 
these lesions, where HPV 6 and 11 are the most common types
128
. Almost all cases of condylo-
mata acuminate have been found to contain HPV when investigated by deep sequencing
128
.  
Another, rather rare condition associated with HPV is recurrent respiratory papillomatosis 
(RRP), which just as condylomata acuminate, is mainly associated with HPV 6 and 11 
129,130
. 
The condition can have either a juvenile onset or an adult onset and the incidence was 
0.54/100,000 in adults and  0.17/100,000 in children in a Norwegian study
131
. In a study from 
northern Sweden, the median age of diagnosis was at 32 years of age
132
. So far, treatment for 
RRP has been considered symptomatic rather than curative although there have been some re-
cent progress using combination therapies
133
.  Eventually, a small subset of RRP patients will 
develop malignancies of the respiratory tract
130
.  
Sinonasal papilloma is another ailment affecting the respiratory tract, and a substantial fraction 
of these have also been found to contain HPV
134
.  
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Two other rare conditions associated with HPV are epidermodysplasia verruciformis (EV) and 
focal epithelial hyperdysplasia (FEH), also known as Heck’s disease. EV is a condition in which 
the patient’s immune system is incapable of handling certain HPV infections caused by HPV 
types such as 5 and 8, and patients develop skin lesions in the form of scaly macules and papules 
on the skin
135,136
. Patients with EV is also at a higher risk of developing skin cancer due to ma-
lignant transformation of the lesions
137,138
. FEH on the other hand, is a benign condition mainly 
associated with HPV 13, and 32 in which numerous papules develop in the oral cavity
139–141
. 
Both of these conditions also have a genetic component which is made evident by the existence 
of families with a very high incidence of disease
142–146
. Especially for FEH, there is also a pat-
tern where certain ethnic populations have an increased incidence of the condition
147
.  
1.9 HPV EPIDEMIOLOGY 
A large meta-analysis, which included one million women with normal cytological findings 
concluded that the estimated global cervical HPV prevalence was 11.7%
148
. The data also 
showed a peak in HPV prevalence in adolescents and young adults followed by a second peak in 
the middle aged
148
. The most commonly found HPV types in these women were HPV 16, 18, 
52, 31, 58, 39, 51, and 56, with 22.5% of all infections being caused by HPV 16
148
. In a study 
performed by our research group at a Stockholm youth clinic before the introduction of public 
HPV vaccination, the highest prevalence was seen in women of 21 years of age where 73% were 
positive for HR HPV
149
. The age distribution pattern seen in these studies is not mirrored in the 
prevalence of anal HPV in men who have sex with men (MSM). In a study from the US, 57% of 
MSM were shown to be positive for anal HPV, with little variation over age groups
150
. 
A proportion of healthy subjects of different ages have been shown to have HPV DNA present 
in the oral cavity. The reported prevalence of oral HPV varies; however, the trend seems to be 
towards a low prevalence in pre-adolescents and adults of the general population and towards 
higher figures in sexually active youth
151,152
. In our previous study from our research group, oral 
HPV prevalence in non-vaccinated young adults at a Stockholm youth clinic was high at 
9.3%
153
. Similar figures have since been reported for certain high risk groups including MSM 
attending a sexual health clinic in London 
154
. Even higher numbers were reported for at-risk 
women in Ho Chi Minh City where a total of 24.6% were positive for at least one HPV type by 
oral rinse and for women below 20 years of age in Yucatan, where 24.5% where positive for at 
least one HPV type by buccal swab
155,156
. Other studies, e.g. a study from the National Health 
and Nutrition Examination Survey in the US found a lower oral HPV prevalence of 3.8% in the 
oral cavity of civilian, noninstitutionalized women
157
.   
Some studies have reported that also new-born infants can harbor oral HPV, suggesting a route 
of vertical transmission from mother to child
158
.  
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1.10 HPV DETECTION METHODS 
1.10.1 Sampling methods and sample types  
To detect HPV in tumor samples, the type of sample obtained and the methods used for sample 
preservation play an important role.  
Tumor samples that are available are often formalin-fixed paraffin embedded (FFPE) samples or 
more seldom fresh frozen tumor samples. DNA and RNA can be extracted both from FFPE 
samples or fresh frozen samples
159
. However, if the FFPE has been stored for many decades its 
quality may be affected and the ability to detect longer fragments of nucleic acids can be abro-
gated
160,161
.  
To detect HPV in oral samples, from healthy individuals or cancer patients, swabs or oral rinses 
can be used, yielding comparable results with regard to HPV prevalence
162
. The liquid in which 
the sample is collected may be of importance as certain brands of mouthwash liquid have indi-
cated to have a better performance with regard to i.e. DNA quality
163
. Other considerations in 
oral sampling include salivary production and whether the person who is being sampled has in-
gested any food or beverage close to the time of sample collection.  
Swab samples are also frequently being used for detection of HPV in cervical specimens and to 
a certain extent for obtaining genital samples from men
164,165
. While swab samples from women 
are generally considered a reliable method of HPV detection, genital HPV sampling from men is 
more difficult and often requires combinatory approach of exfoliation of cells from various geni-
tal subsites and collection of urine
166,167
.  
1.10.2 Direct and indirect detection of presence of HPV 
In clinical settings, p16 immunohistochemistry (IHC) is still commonly used as a surrogate 
marker for HPV in cancer diagnostics. As earlier mentioned and also pointed out by many, this 
practice is suboptimal as p16 status and HPV status, as defined by more direct methods of detec-
tion are often discordant
119,168,169
 Today, p16 is mostly considered as a useful marker when used 
in combination with other methods detecting viral DNA or RNA
170
.  
One of the most frequently utilized ways of detecting HPV DNA is by PCR. The regions com-
monly amplified using this method are L1, E6 and E7. PCR amplification of the relatively well 
conserved L1 region enables for detection of a wide range of HPVs using either primers with 
degenerative nucleotides or consensus primers which can bind to a large variety of HPVs when 
using a relatively low annealing temperature
171
. The different HPV types detected by these 
methods can then be identified using various detection methods such as sequencing, or bead-
based methods like Luminex MagPix. Some studies have suggested that a lower false negative 
rate can be achieved by using E6 or E7 primers, since these regions are more likely to be re-
tained over the course of disease progression and/or chromosomal integration, however, since 
these genomic sequences differ more across HPV types, they may be more suited to detect spe-
cific HPV types than for use in larger screenings
172
.  
 15 
 
Another method, which has received more attention in recent years, is the detection of E6/E7 
mRNA, this method is often considered the preferred method of detecting an active HPV infec-
tion
173
. As mentioned above, detection of the oncogenes E6 and E7 should be possible in a large 
proportion of HPV associated lesions. By detecting E6 and E7 rather than L1, you gain the add-
ed benefit of being able to identify HPV that is transcriptionally active and thus has a greater 
chance of being clinically relevant. Detection of HPV mRNA can be done either by PCR or by 
mRNA in situ hybridization (ISH). However, for detection of mRNA the samples should ideally 
be rapidly fresh frozen, or possibly formalin fixed
159
. 
1.11 HPV VACCINATION 
1.11.1 Prophylactic HPV vaccination 
Since ancient times, attempts have been made at inoculating individuals with infectious agents to 
give rise immunity and prevent serious disease. Since then, the art of vaccine development has 
grown increasingly sophisticated and today, some main categories of vaccines can be identified; 
inactivated, live attenuated, toxoid, conjugate vaccines and subunit vaccines, where the prophy-
lactic HPV vaccines in current use belong to the latter category. In the 1980’s, it was possible to 
effectively vaccinate cattle against papillomaviruses using L1 and L2 based vaccines and in the 
1990’s, highly immunogenic VLPs were produced against human papillomaviruses174,175.  
In 2006, the first prophylactic vaccine against HPV, Gardasil became available on the Swedish 
market. In 2007, the second vaccine Cervarix became available. Both of the vaccines are protec-
tive against HPV 16 and 18, which are the types most commonly found in cervical cancer. Gar-
dasil is also protective against an additional two types, namely, types 6 and 11, which are com-
monly found in condylomata acuminate. Gardasil is indicated for use in both girls and boys 
from 9 years of age to protect against anogenital cancers, precancerous lesions of cervical, 
vulvar, vaginal, and anal cancers, and condylomata acuminate, while Cervarix is recommend-
ed for use in girls from 9 years of age against precancerous lesions of cervical cancer
176,177
 
As mentioned above, both Gardasil and Cervarix are subunit vaccines whose active compo-
nent consists of VLPs of specific HPV types. The VLPs of Gardasil are produced in yeast, 
whereas the VLPs of Cervarix are produced in insect cells. Both vaccines are adjuvanted with 
aluminum based adjuvants
177,178
. 
Since the introduction of the two first HPV vaccines, vaccine development has continued. Gar-
dasil 9 is the first FDA approved nona-valent HPV vaccine. In addition to protecting against 
HPV 6, 11, 16 and 18 as the quadrivalent Gardasil, the nona-valent Gardasil also protects against 
HPV 31, 33, 45, 52, and 58 and is indicated for use in both girls and boys from 9 years of age 
to protect against anogenital cancers, precancerous lesions, and condylomata acuminate
176
.  
When implementing large scale vaccination programs, there is a great chance that some individ-
uals will not be vaccinated, either due to medical reasons or to personal beliefs. To a certain ex-
tent, these individuals will obtain protection from the disease as well, given that the proportion 
of vaccinated individuals is sufficiently high. This phenomenon is named “heard immunity”. 
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The dynamics of sexually transmitted infections are unique in the sense that vaccinating one sex 
will grant protection for the other sex as well - at least for the individuals who have exclusively 
heterosexual relationships
179
.  
 
Figure 6. Herd Immunity. In scenario A, infection spreads throughout the population. In 
scenario B, the vaccinated individuals protect those at risk and the infection is contained.  
1.11.2 Therapeutic HPV vaccination 
Attempts at curing HPV related disease using vaccination have been made even before the virus 
was identified. Since long, extracts of papillomas have been used in veterinary practice with 
some success
180
. In the 1960ies, trials on autogenous laryngeal papilloma vaccines were per-
formed in humans. Although the vaccines were somewhat effective in limiting the spread of 
papillomas and even causing them to regress, far from every patient benefitted from the treat-
ment and some patients were forced to discontinue the treatment due to adverse events
181
. Over 
time, the approaches towards therapeutic papillomavirus vaccination grew more sophisticated. 
After the invention of recombinant technology, it became possible to elicit immune responses 
using recombinant viral proteins, a principle that was tried out in cattle in the early 1990ies
182
. 
At this time, Campo et al. showed that it was possible to vaccinate calves both prophylactically 
and therapeutically against bovine papillomavirus (BPV) 4, a mucosal BPV type causing papil-
lomas of the bovine alimentary canal
182
. Major targets in the development of therapeutic vac-
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cines for use in humans have been the E6 and E7 proteins of HR HPV types. Examples of thera-
peutic vaccines that have been developed include a Venezuelan equine encephalitis based vac-
cine using a fused HR HPV E6 and E7, and the previously mentioned example of Lactobacillus 
Casei expressing modified E7, however, to date, no therapeutic HPV vaccine is available on the 
market
55,183
.  
1.11.3 Vaccine controversy 
While vaccination arguably can be considered as one of humanities greatest innovations and 
triumphs, the implementation of vaccination programs is still received with some suspicion by 
the general public. Concerns that are being raised include the fear of adverse effects due to auto-
immunity or toxicity caused by vaccine components such as adjuvants, corruption within the 
pharmaceutical industry  as well as government directed efforts for population control
184,185
. 
Although it is easy to dismiss these concerns as ignorance and conspiracy theories, it is im-
portant to remember that the history of medical science is indeed littered with some true low 
water marks. The infamous Nazi experiments on human physiology, as well as the Tuskegee 
syphilis study, and the Vipeholm experiments on dental decay constitute examples of what is 
today to be deemed severe scientific misconduct
186–188
.  
Also, despite the best intentions, not every new vaccine or therapeutic agent have the desired 
safety and efficacy when taken into human trials or clinical use. One such example is the unex-
pected side effects that surfaced after the large scale implementation of the H1N1, or swine flu, 
vaccine
189,190
.  
Not surprisingly, also the HPV vaccines are subject to some controversy. Regarding the HPV 
vaccines, some main causes of concern have been the fear of post-vaccination infertility due to 
ovarian failure as well as onset of postural tachycardia syndrome (POTS). Clinical data on these 
syndromes in relation to vaccination remain scarce; regarding primary ovarian failure, only a 
handful of cases have been reported and also concerning POTS, the evidence is limited and non-
conclusive due to small sample size and poor study design
191,192
. This does not mean that the 
studies should be dismissed. Post-vaccination monitoring of adverse events remains of immense 
importance to identify potential risk-groups and in the development of new vaccines.  
In the case of the reported incidences of POTS, the European Medicines Agency (EMA) under-
took an investigation which showed no increase in the overall incidence of the condition in the 
relevant age group. The EMA concluded that there was no evidence supporting the notion that 
HPV vaccination would be causing POTS
193
.   
1.11.4 Vaccine safety and efficacy 
Despite frequent claims of the contrary, the HPV vaccines currently on the market were exten-
sively studied prior to licensure and have been deemed to have acceptable risk-benefit ratios. In 
August 2015, there were 84 national programs and 38 pilot programs ongoing which is resulting 
in a very high number of people vaccinated worldwide, facilitating large scale epidemiological 
studies
194
.  
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So far, no large scale studies of HPV vaccine safety have shown the vaccines currently in use to 
be associated with any serious adverse effects. The side effects that have been described are of-
ten located to the injection site and include pain, swelling, erythema, and pruritus, as well as 
systemic side effects such as nausea, syncope, headache and pyrexia
195,196
. Also in pregnant vac-
cine-recipients, no concerning pattern of adverse events have been observed
196
.  
Since cancer development takes many years, it is still not possible to detect changes in the inci-
dence of HPV related cancers; however, the reduction seen in precancerous lesions is highly 
encouraging and provides reliable evidence of vaccine efficacy
197,198
.    
1.11.5 Upscaling of vaccination programs 
It has been demonstrated that HPV vaccination is primarily beneficial before first exposure to 
the virus. Because of this, vaccination programs have primarily been aimed at young girls that 
are statistically unlikely to be sexually active, and, have often been performed in a school based 
setting. This approach may well lead to a good vaccine uptake in the target population, however, 
since only selected age groups are targeted this leads to a suboptimal protection in other cohorts. 
To provide a better coverage on a population basis, catch-up vaccination of older girls has been 
used in some regions.  
Although HPV vaccination has been suggested to be less efficient in older women than in young 
girls, catch-up vaccination seems to be both beneficial and safe. A systematic review by Couto 
et al. reporting on 13 randomized control trials (RCTs) of women until the age of 45, including 
close to 40.000 individuals, showed a reduced risk for all VIN2+ and VaIN2+, HPV related 
CIN2 and condylomata acuminate. Serious adverse events were not more common in the catch-
up vaccinated group as compared to vaccination in young girls
199
.  
Increased vaccination coverage in adolescent girls has been estimated to be the most cost effec-
tive mean of upscaling a vaccination program targeting only 11-year old girls when considering 
cervical prevalence of HPV16 and 18
200
.   
Another option in increasing vaccination coverage is to also include young boys. This effort 
alone seems to be less effective than vaccinating older girls; however, these estimates usually do 
not include other outcomes than cervical disease and is also dependent on what percentage of 
girls that are vaccinated. Another obstacle that has emerged in areas that already offer gender 
neutral vaccination programs is the fact that boys and their parents simply do not know that vac-
cination is beneficial and readily available
184
. In 2013, the vaccination coverage of boys in the 
United States was 34.6% and dose series completion was 13.9%
201
.   
Whether upscaling of vaccination is cost effective in absolute figures, as measured by e.g. cost/ 
quality-adjusted life year gained, is dependent on a number of factors including predicted vac-
cine efficacy, base line HPV prevalence, vaccine coverage, number of birth cohorts included and 
vaccine cost
202
. One attractive option in addressing the latter is to oversee the number of doses 
needed to give adequate protection. Studies have shown that two doses, and maybe even one 
dose, can elicit antibody responses comparable to that of a three dose regimen
203,204
. If the re-
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sponse of such a regimen would prove stable over time, this might well be a feasible option to 
decrease the cost of the vaccination program and achieve better vaccination coverage.    
1.12 SEXUAL HABITS IN YOUTH  
During adolescence and young adulthood, most individuals become sexually active. This is of-
ten referred to as the sexual debut, and the age at which a person experiences this event is known 
as the sexarche.  Sexarche is on average said to occur sometime in the late teens and, about one 
year earlier in men than in women. The mean age of sexarche varies, both over time and over 
geographical regions. Other aspects such as gender, sexual orientation and sociodemographic 
aspects also play a role in when a person becomes sexually active. Factors associated with an 
earlier sexual debut include poor impulse control, childhood behavioral problems, and for some 
behaviors, high BMI 
205–207
. Conversely, a Swedish study showed a later sexual debut to be cor-
related to a number of factors including having caring or overprotective fathers, and parents born 
outside of Europe, however, the most important factor was a lower sexual desire
206
.  
Overall, the mean age of sexual debut seems to be decreasing in many parts of the world. The 
reasons for this may include an increased cultural acceptance as well as greater opportunity to 
intermingle with individuals of similar age as the world becomes increasingly urbanized. Never-
theless, sexual habits remain a sensitive topic and behavioral research has to rely on self-
reported information which is inherently prone to bias. This issue is made evident when compar-
ing questionnaire administration modes. A systematic literature review by Langhaug et al found 
that response rates as well as reported behaviors differed quite extensively between administra-
tion modes. In general, lower frequencies of different sensitive behaviors were found using self-
administered questionnaires or face-to-face interviewing, as compared to when using audio 
computer-assisted survey instruments, highlighting the influence of social desirability norms in 
these types of studies
208
. In Sweden, the mean age of sexual debut appears stable at somewhere 
between 16 and 17 years of age since the 1960’s while the mean age of sexual debut seems to be 
decreasing for both sexes in the US
209,210
.  
One change that has taken part over last decades in Sweden is an increase in the average number 
of lifetime partners. In 1967, the median number of sexual partners reported by a selection of 
Swedes of18-74 years of age was 1.4 for women and 4.7 for men. In 1996 the corresponding 
figures were 4.6 and 7.1 respectively and similar trends have been shown in the US
209,210
.  
The greatest degree of sexual intermingling seems to take place in adolescence and early adult-
hood. This trend also reflects in the incidence of sexually transmitted infections (STIs). It has 
been estimated that 50% of the 19.7 million incident infections of STI in the US were among 
young men and women aged 15-24 and the majority of infections were caused by HPV
211
. Simi-
larly, the age-specific incidence of cervical infections prior to the introduction of public HPV 
vaccination shows a peak in the early twenties
212
. As a side note, prevalence data from a number 
of countries display a second peak in the late forties which may be related to a high rate of di-
vorce and children being likely to have left the home
212
. 
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Research on trends and behaviors in youth remain crucial for understanding the spread of sex-
ually transmitted infections (STIs) and their associated complications. 
1.13 SEXUALLY TRANSMITTED INFECTIONS AND REPRODUCTIVE HEALTH 
IN YOUTH 
Together with educational interventions and vaccination against some pathogens, youth clinics 
constitute an important aspect of primary STI prevention.  In Sweden, youth clinics are available 
for individuals up to 23 years of age. These clinics are found in most larger communities and 
offer counselling, advice on contraception and family planning as well as testing for STIs.   
Studies have shown Sweden to have the highest rate of abortions in the Nordic countries and a 
high incidence of chlamydia acuminate
213,214
. One of the explanations for these observations 
may be inconsistent condom use and a relatively low age of sexarche in international compari-
son. A Swedish study also showed positive association between oral contraceptive (OC) use and, 
nationwide abortion and chlamydia infection rates
214
. This association may be explained by a 
lower use of condoms in individuals taking OC as well as failure by individuals to follow the 
instructions for use of the drug
214
. Similarly, it has been shown that cervical HPV infection is 
indeed very common in young Swedish women
153
.  
The practice of “safe sex” using barrier type contraceptives such as condoms and dental dams is 
inconsistent in adolescents and young adults in Sweden
215
. Even though many know how to pro-
tect themselves against STIs and unwanted pregnancies, this does not translate into safe sexual 
practice
215,216
. The reasons for not using condoms during sexual contact include convenience, the 
belief that it condom use would make sex less enjoyable and the fear that sexual partners may 
react negatively to suggested condom use
216,217
. This issue is being addressed through informa-
tional campaigns and by handing out free condoms in different contexts. 
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2 AIMS  
 To examine oral HPV prevalence, and its association with HPV vaccination status in 
youth at a youth clinic in Stockholm and in high schools in a middle-sized Swedish 
municipality (Papers I, III, and IV) 
 
 To investigate how HPV vaccination status relate to sexual experiences and sexual risk-
taking in a cohort of Swedish youth  (Paper II) 
 
 To examine type-specific cervical HPV prevalence, and its association with HPV 
vaccination status in youth at a youth clinic in Stockholm  (Papers III, and IV) 
 
 To evaluate how commonly HPV can be found in hypopharyngeal cancer and to what 
extent this correlates to p16 expression  (Paper V) 
 
 To determine if there has been in increase in the proportion of HPV positive 
hypopharyngeal cancer over time (Paper V) 
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3 MATERIAL AND METHODS 
The studies included in this thesis were approved by a Regional Ethical Review Board and 
conducted in accordance with ethical permissions Regional Ethical Review Board of Uppsala 
No. 2010/369, Regional Ethical Review Board of Stockholm No. 2012/1756-31/2, No. 
2008/870-31/4, No. 2009/1147-31/2, and No. 2009/1278-31/4.  
Studies on sexual habits and HPV prevalence in healthy subjects were cross-sectional and did 
not individually consider temporality. 
The patient material and samples from healthy subjects were collected from several source 
populations. Diagnosis codes used in the classification of hypopharyngeal cancers in Paper V 
was in accordance with the ICD-classification system ICD10. The study design and the re-
spective cohorts of patients and healthy subjects are described in further detail below.    
3.1.1 Paper I  
In total, 335 third-year high school students aged 17–21 years (median age 18 y), from 13 
schools in a municipality with a population of 140,000, were examined for oral HPV preva-
lence. Data were also collected on sex, and HPV vaccination status of the participants. In 
addition, the students answered a questionnaire, and data on sexual experiences could thus be 
accessed (for details of the questionnaire see paper 2). This study was cross-sectional in de-
sign. 
3.1.2 Paper II 
355 female third grade high school students aged 17–21 years (median age 18 y) were in-
cluded in this study of which 338 answered the questionnaire in the classroom setting and 17 
who participated by postal questionnaire. Questions on HPV vaccination were not included in 
the original study and this study should thus be considered cross-sectional as information is 
only gathered at one time point.  
3.1.3 Paper III 
In total, 211 women and 87 men aged 15-23 years, attending a Stockholm youth clinic, par-
ticipated in the study. A total of 287 mouthwash samples were collected in 50% Listerine and 
water. The study is a follow-up on a previous study on HPV prevalence conducted at the 
same clinic. 
3.1.4 Paper IV 
In this study, HPV prevalence was investigated in cervical, and mouth wash samples collect-
ed between October 2014 and May 2015. Mouthwash samples were collected from 335 
women and 112 men. Cervical samples were collected from 338 women. The study was an 
extension of the study presented in Paper III.  
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3.1.5 Paper V 
In this follow up study, HPV prevalence and p16 overexpression was examined in formalin 
fixed paraffin embedded (FFPE) tumor biopsies of 82 patients diagnosed with 
hypopharyngeal cancer diagnosed in 2008-2013 at the Karolinska University Hospital. The 
survival analysis included 142 hypopharyngeal cancer patients diagnosed between the years 
of 2000 and 2013 at the Karolinska University Hospital, which were treated with curative 
intent and had a 3-year follow-up period.  
3.2 DNA EXTRACTION 
In order to detect the presence of HPV DNA in the samples, DNA was extracted using one of 
the following DNA extraction kits: 
 High pure PCR template preparation kit (Roche®) (for cervical swabs) 
 Gentra Puregene Buccal Cell Kit (Qiagen®) (for mouthwash samples) 
The High pure PCR template preparation kit is a spin column based method which was used 
for cervical swab samples. The Gentra Puregene Buccal Cell Kit, which functions through a 
modified “salting-out” mechanism, was used for extraction of DNA from buccal cells in 
mouth wash samples. Both protocols have the potential to yield high quality DNA suitable 
for a range of downstream applications.  
3.3 HPV DETECTION 
Presence of 27 mucosal HPVs including all known HR HPVs was performed using a bead-based 
multiplex assay as follows: 
The DNA was amplified using BSGP5+/6+ HPV L1 consensus primers, and specific primers 
for HPV 16 and HPV 33 E6, and β-globin along with the Qiagen Multiplex PCR kit (Qi-
agen®). Specific HPV types were the detected using a bead-based MagPix instrument (Lu-
minex Inc. ®). The micro-beads were coupled to the HPV type specific probes on-site in the 
laboratory. The assay used in these studies contained specific beads for simultaneous detec-
tion of 27 mucosal HPV types, namely HPV6, 11, 16, 18, 26, 30, 31, 33, 35, 39, 42, 43, 44, 
45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, and 82. Bound DNA was detected using 
fluorescent r-phycoerythrin which was linked to the PCR products through a biotin-
streptavidin complex. This method of HPV detection is semi-quantitative in nature and ena-
bles detection even of very few viral genomes. A dilution series of DNA from the HPV 16 
positive cell line SiHa was used as positive control for HPV DNA. The detection of β-globin 
was used as a positive control for the amplification of cellular DNA. 
3.4 IMMUNOHISTOCHEMISTRY 
4μm sections of formalin fixed paraffin embedded (FFPE) tumor material was de-
paraffinized in xylene of decreasing concentrations and rehydrated in ethanol. Antigen 
retrieval was done by heating of the samples in citrate buffer in a microwave oven.  
Endogenous peroxidase was blocked by incubation with 0.03% H2O2. Sections were stained 
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for p16 using the E6H4™ Mouse monoclonal antibody, CINtec® p16 histology (Ventana, 
Tucson, Arizona) followed by a secondary biotinylated horse anti-mouse antibody (Vector 
Laboratories, California) diluted 1:200. ABC-HRP (Vectastain, Vector labratories) was then 
used for antigen detection and the slides were developed with chromogen 3’ 
diaminobenzydine (DAB). The slides were counterstained with hematoxylin and mounted 
using Pertex® mounting media (Histolab, Göteborg, Sweden) and evaluated by two 
researchers. Samples with strong staining in more than 70% of the tumor cells were 
considered p16 positive.  
3.5 QUESTIONNAIRE 
The questionnaire was originally used by some of the co-authors in a previous study on 
sexual habits in youth. For this study, the questionnaire was modified to also include 
questions on HPV vaccination. 
The instrument used in this study had a total of 48 multiple-choice questions, covering 
different aspects of sexual health and behaviors as well as questions on HPV vaccination. The 
questionnaires were placed in envelopes by the students and anonymized before analysis. All 
students present in the visited classrooms received a small gift bag with condoms, candy and 
a lottery ticket. 
3.6 STATISTICAL ANALYSIS 
Fischer’s exact test or Chi-squared test was used for categorical data. In paper 1, confidence 
intervals for prevalence data were calculated using a 1-sample proportion test with continuity 
correction. In paper 5, survival data were stratified on HPV 16 and p16 status or p16 alone 
and analyzed for overall and disease specific survival by nonparametric log-rank test. All 
statistical analyses were performed in R Statistics version 2.15.3 with the exception of paper 
2 where IBM Statistical Packages of Social Sciences, SPSS 20 was used. 
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4 RESULTS AND DISCUSSION 
4.1.1 Paper I 
Oral and cervical HPV was shown to be common at a Stockholm youth clinic in youth who 
were not vaccinated against HPV in studies performed 2008–2010 and 2009–2011. In a 
previous study by our research group, oral HPV prevalence in young adults not vaccinated 
against HPV at a Stockholm youth clinic was 9.3%
153
.
 
An oral prevalence of 9.3% can be 
considered somewhat high by international standards, as a 2010 meta-analysis found an 
average HPV prevalence of 4.5%
218
. Similarly, cervical HPV was high by international 
standards at 70%
219,220
. The question was raised whether or not this high prevalence could be 
due to the fact that the youth clinic constituted a selected cohort of high risk of contracting an 
HPV infection. Consequently, we decided to examine whether the prevalence was equally 
high in another, less selected cohort of Swedish youth. 
In conjunction with a study on lifestyle and sexual habits which was a collaboration between 
researchers from several Swedish universities, we here collected mouthwash samples and 
vaccination data from Swedish 3
rd
 year high school students from a middle sized municipality 
in Sweden. At the same time, a questionnaire study was carried out to shed some light on the 
sexual experiences of the young adults participating in this study- an aspect that was missing 
in the original youth clinic study (for details see Paper II). The results of these studies were 
interesting in that the HPV prevalence was much lower (1.8%) than in the original youth 
clinic study. Methodologically, the studies were similar although three additional HPV types 
were screened for in this study.    
Of the women participating in this study, 64% had received at least one dose of HPV vaccine. 
Of all oral samples, 1.8% were positive for the presence of HPV DNA, and there was no 
statistically significant difference between men and women.  Four of the women tested 
positive for HPV 16, all of which were vaccinated, but none before their sexual debut. The 
fact that vaccination took place after the sexual debut means that the virus could have been 
acquired prior to vaccination. No statistically significant difference could be seen in the oral 
HPV prevalence between vaccinated and non-vaccinated women.  
The prevalence of oral HPV was low in this study, as compared to the original youth clinic 
studies. One thing that should be noted is that MFI values in the MagPix analysis from 
mouthwash samples are usually many times lower than what is found in other sample types 
such as cervical samples, and tumor biopsies. Nevertheless, results from similar studies have 
given similar results
221,222
. We therefore speculated that the lower prevalence could be due to 
demographical differences, effects of the HPV vaccination, or a combination of both. This 
study contributes to a more accurate picture of HPV prevalence healthy youth as the sample 
is class room based rather than clinical. 
 26 
4.1.2 Paper II 
In the context of the introduction of the HPV vaccines, it was speculated as to whether or not 
getting vaccinated would influence sexual habits in youth. In conjunction with a follow-up 
study on sexual habits in youth, we collected data on HPV vaccination, lifestyle, and sexual 
habits from Swedish high school students one year after the vaccines became free of charge 
for young women.  
Of the 65% of individuals who were vaccinated against HPV, 62% were vaccinated after 
their sexual debut. There were no significant differences between vaccinated and non-
vaccinated individuals with regard to condom use, self-reported STIs, experiences of oral or 
anal sex, or having had a friends-with-benefits relationship. Having had sexual intercourse 
and “one-night stands” was more common in the vaccinated, than in the non-vaccinated 
women (p=0.005, and p=0.046) At the time of the sample collection, 64% of the women in-
cluded in the study reported having received at least one dose of HPV vaccine, albeit on aver-
age one year after sexual debut, suggesting that the lower HPV prevalence could at least in 
part be related to protection from the vaccine. 
This study showed that being HPV vaccinated did not have a major impact on sexual risk-
taking which is in line with a previous study from the U.S
223
. Since the risk of feeling a false 
sense of being protected against STIs in general is a common argument against HPV vaccina-
tion, this study adds information that may be of great benefit for public health. It should also 
be noted that due to the cross sectional nature of this study, no conclusions can be drawn re-
garding causality. This means that the observed differences between vaccinated and non-
vaccinated women may be a result of women with higher risk taking choosing to get vac-
cinated to a larger extent.  
 It should also be noted that the administration mode of questionnaires can affect the results 
and that such effects can differ between different populations. Additionally, repeating this 
study in other populations would improve the generalizability of the results. 
4.1.3  Paper III 
In two previous studies, in 2008–2010 and 2009–2011, our group had studied oral and 
cervical HPV prevalence in youth aged 15–23 years and found a very high oral and cervical 
HPV prevalence. In 2013, in Paper I, we therefore studied oral HPV prevalence in a different 
cohort, i.e. in of Swedish high school students and here oral HPV prevalence was much lower 
than in our initial studies at the youth clinic. However, by this time 65% of the female high 
school students had been HPV vaccinated. These results urged us to return to the Stockholm 
youth clinic visited in the original study to do a follow-up study, examine whether oral and 
cervical HPV prevalence remained at a high level in that setting also after the introduction of 
public HPV vaccination.   
In this study, we could see a lower oral HPV prevalence also in the youth clinic cohort of 
1.4%, and that oral HPV-prevalence which was very similar to that among high school stu-
dents
224
.  Furthermore, it was clear that that the vaccination coverage of the females in both 
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the school-based study (Paper I in this thesis), and in the present study was quite similar 
(1.8%  and  1.4%  respectively), and it was reasonable to assume that the fact that we were 
now investigating largely vaccinated cohorts may account for the difference observed in 
prevalence.  
Methodologically, this study was similar to the original youth clinic study with the addition 
of screening for three extra HPV types. In this study, a proportion of the mouth wash samples 
were collected in the Scope® Original Mint mouthwash rather than Listerine®. This did not 
seem to affect the proportion of HPV positive samples. 
In this study, 73% of the women donating a cervical sample were vaccinated against HPV, 
although we did not have data on whether vaccination occurred before after their sexual de-
but. Oral HPV DNA was detected in 1.4% of the young men and women donating a mouth-
wash sample with no difference between vaccinated and non-vaccinated individuals, or be-
tween women and men. The prevalence in this population was significantly lower than what 
was seen in the previous youth clinic study on oral prevalence from 2009-2011 (p < 0.00001). 
Cervical HPV DNA was detected in 61% and 70% of the samples of HPV- vaccinated and 
non-vaccinated women respectively. HPV 16, 31 and 70 were significantly less common in 
vaccinated than in non-vaccinated individuals. While HPV 16 was expected to have de-
creased and there have been previous reports of cross protection against HPV 31, the ob-
served protection against HPV 70 has not been previously reported
225,226
. This finding may 
not be of major clinical relevance as there is little evidence implicating HPV 70 in disease. 
There was also a tendency for the vaccine types HPV18, 6 and 11 to be less common. How-
ever, that there were no significant differences observed in the other vaccine type HPVs can 
be explained by the fact that they simply were not very common to begin with and a very 
large sample size would be needed to see any statistically significant differences in the preva-
lence of these types.  
Further, more drastic, changes in the HPV prevalence among youth can be assumed to occur 
over time when those vaccinated at a young age within the school based vaccination program 
initiated in 2012 will reach the same age as the cohorts included in this thesis. 
4.1.4 Paper IV 
In our study 2013-2014 (Paper III), at the youth clinic in Stockholm, there had been a major 
decrease in oral HPV prevalence, and in cervical samples, total HPV as well as HPV 16 had 
decreased as compared to previous studies 2008-2011 at the same clinic. To detect if these 
changes persisted over time, we extended the study to also include samples from the fall of 
2014 and the spring of 2015. 
During this period HPV-vaccination frequency in women remained stable at 71%.  No data to 
whether it was performed before or after sexual debut were obtained. When combining data 
from 2015 with previous results from 2013-2014, oral HPV prevalence remained low at 
1.5%. Cervical HPV prevalence was 64.6% and 74.5% in vaccinated and non-vaccinated 
women respectively (p = 0.096). HPV 16, HPV 31 and HPV 6 were less common in vac-
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cinated than in non-vaccinated women (p = 0.0006, p = 0.038 and p = 0.009, respectively). 
HPV16 prevalence was also significantly less common in this cohort than in the pre-
vaccination youth clinic study from 2008-2011.  
Methodologically, this study was a continuation of the study presented in paper 3. Here, all 
mouthwash samples were collected in Scope Original Mint Mouthwash.  
Indeed, in this fourth study of this thesis, we found that adding an additional 160 mouthwash 
samples to our previous data did little difference to the total oral HPV prevalence, which re-
mained low (1.5%). It should be noted that MFI values for mouth washes from healthy indi-
viduals were generally much lower than in cervical samples or in mouthwashes from cancer 
patients. It is therefore possible that some proportion of the differences observed may be due 
to minute methodological differences between studies even though we could find no evidence 
of such differences in the laboratory protocols. 
Over the studies performed on HPV and sexual habits in youth, we could see that after the 
introduction of public HPV vaccination, vaccination coverage increased from 10% in the 
original youth clinic studies to stabilize at a level of about 70% in girls. In the same time pe-
riod, vaccinated boys were extremely rare in every study. The fact that cervical HPV 16 was 
less common in both vaccinated and non-vaccinated women as compared to what was ob-
served in the original 2008-2012 youth clinic study, which included non-vaccinated women 
indicates a certain degree of heard immunity effect
149
. This also seemed to be the case with 
regard to oral HPV prevalence, since both vaccinated young women and non-vaccinated 
young women and men had a lower oral HPV prevalence than what was observed in the orig-
inal youth clinic studies. The decrease from 9.3% to 1.5% was indeed rather dramatic, even 
when considering potential heard immunity and cross protective effects
153
. As no socio-
demographic data were collected from the study subjects we cannot address whether any such 
changes had taken place in the population visiting the clinic, however, no major changes in 
the daily work had been reported by the midwives at the clinic. 
This study indicates that oral HPV prevalence have decreased after the introduction of the 
introduction of the HPV vaccines, which may have a substantial impact on the future burden 
of head neck cancers. 
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Figure 7. Type specific cervical HPV prevalence by HPV vaccination status 
and in comparison to previous data from the same clinic (Paper III) 
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4.1.5 Paper V 
Based on the fact that the proportion of HPV positive tonsillar and base of tongue cancer has 
been increasing in the last few decades, we wanted to investigate if a similar increase had 
taken place in hypopharyngeal cancers- a cancer type with a particularly poor prognosis. 
During the period of 2000-2007 we had previously reported an HPV prevalence of 3.7% in 
hypopharyngeal cancer in Stockholm, and we anticipated that an increase in HPV prevalence 
may have occurred during the years 2008-2013. The goal of this investigation was to test this 
hypothesis. 
Of the hypopharyngeal tumor biopsies in the present study, 3/82 (3.7%) were HPV16 DNA 
and p16 positive, while 12/82 (14.6%) were p16 positive, data similar to the study 2000-2007, 
thus there was no increase of HPV-prevalence over time. Combining the two studies, and 
including 142 hypopharyngeal patients diagnosed 2000-2011, the overall 3-year survival, was 
significantly better for those with HPV16 DNA and p16 positive tumors as compared to 
survival of the others (86% vs. 31%, p=0.0185). This is similar to what was previously shown 
for tonsillar and base of tongue cancer
122
. We could find no evidence of an increase in the 
proportion of HPV positive hypopharyngeal cancer. 
In similar international reports estimates for the HPV attributable fraction in hypopharyngeal 
cancer has varied between 0-82% and in a meta-analysis the average proportion of HPV 
positive hypopharyngeal cancer was 21%. Thus, our data showed a relatively low prevalence 
of HPV in hypopharyngeal cancer, despite the fact that the prevalence of HPV is high in 
oropharyngeal cancer in the Stockholm region. 
P16 expression was found to be a poor surrogate marker for HPV in this sample since 12/82 
(14.6%) of samples were p16 positive; all of which but three were found to be HPV DNA 
negative. 
To conclude, HPV16 prevalence was 3.7% and there was no detectable increase in the HPV 
attributable fraction in this setting. p16 was not a suitable surrogate marker of active HPV 
infection in hypopharyngeal cancer since the majority of p16 positive tumors here were HPV 
DNA negative. One alternative way of detecting active infection in this sample type could be 
using HPV RNA ISH; however, the method has not been evaluated for this sample type and it 
has been suggested that the assay may not provide satisfactory discrimination between DNA 
and RNA
173,227
. The fact that patients with HPV positive hypopharyngeal had a good clinical 
outcome is indeed interesting; however, the results should be taken with some caution due to 
the low sample number. Further studies are needed to confirm this finding. 
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5 SUMMARY AND CONCLUSIONS 
 
 There was a relatively low prevalence of oral HPV (1.8%) in third year high school 
students in one Swedish municipality (Paper I) 
 Although 65% of the women in the third year of high school in one municipality in 
Sweden were vaccinated against HPV, most were vaccinated after their sexual debut 
(Paper II) 
 No differences were seen in  condom use or STIs between vaccinated and non-
vaccinated women in this cohort, however, experiences of sexual intercourse and one-
night stands were more common in vaccinated, than in non-vaccinated women (Paper 
II) 
 In 2013-2014, oral HPV prevalence was low at a Stockholm youth clinic as compared 
to previous data from the same clinic (1.4% as compared to 9.3% in 2009-2011) 
(Paper III) 
 Cervical HPV 16 and 31 were significantly less common in vaccinated than in non-
vaccinated women in both Paper III and Paper IV. HPV 70 was significantly less 
common only in the first, and HPV 6 was less common only in the second of the two 
studies (Paper III and Paper IV) 
 HPV DNA was rarely detected in hypopharyngeal cancer from the Stockholm region 
and the prevalence remained stable over time (Paper V) 
 Overexpression of p16 was not a reliable surrogate marker for HPV in these samples 
(Paper V) 
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